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Background
• Hypoxia changes the tumor microenvironment to 
increase cancer cell metastasis and resistance to 
therapy
• Hypoxia Inducible Factor (HIF), upregulates 
glycolysis and angiogenesis in response to oxygen 
stress. 
• Carbonic Anhydrase IX (CAIX) is a downstream 
enzyme in the HIF pathway and a biomarker of cell 
hypoxia.
• It is known that hypoxia is influenced by two factors: 
oxygen consumption rate (OCR) and access to 
oxygen by tumor vasculature.1
• It is shown that OCR significantly decreased in 
Enoase1 (ENO1)-deleted cells followed by enolase 
inhibition.2
• We hypothesize that treatment of ENO1-deleted 
cells with an enolase inhibitor will decrease 
hypoxia within the tumor 
Methods
Cell Lines:
• ENO1-deleted: D423-MG (D423) cells
• ENO1-intact: D423-ENO1 cells are the 
isogenic control cell line where ENO1 is 




• HEX  effectively treats ENO1-deleted cells by reducing  
tumor hypoxia responsible for cancer cell migration and 
quiescence.
• Integrated therapies targeting the angiogenesis responsible 
for hypoxia in combination with Enolase inhibition and 
radiation therapy may have more potent effects on ENO1-
WT cells.
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Objectives
We are investigating the mechanism of hypoxia 
reduction in the tumor microenvironment by 3 strategies 
to:
• Determine if there a consistent decrease in CAIX 
activity after shENO2 knockdown in various O2
concentrations
• Determine if enolase inhibition can decrease hypoxia in 
ENO1-deleted cells in culture
• Identify if select sensitivity to Enolase inhibition 
decreases CAIX expression in ENO1-deleted 
subcutaneous and intracranial tumors in vivo
Figure 1. HIF dimerizes in hypoxic microenvironment, targets the 
Phosphoglycerate Kinase (PGK) gene and upregulates the PGK 
enzyme’s activity in glycolysis pathway.
Knockdown of ENO2 by shRNA reduces CAIX activity 
Methods (Cont.)
Figure 2. The anionic charge on HEX at biological pH 
making it less effective in permeating whereas the POM 
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Figure 5. HEX treatment of ENO1-deleted intracranial and 
subcutaneous xenograft tumors consistently decreases CAIX 
expression. (A) After HEX treatment, the center region of the tumor has 
much less CAIX expressed. CAIX staining is less intense and more 
uniform throughout the tumor region, indicating a decrease in hypoxia. 
(B)  After treatment, the center of tumor that was previously saturated in 
CAIX now has only slightly visible staining.(C)  The treated tumor does 
not show significant reductions in CAIX. This is likely a reflection of the 
decreased vulnerability of ENO1-intact tumors to enolase inhibition. (D) 
HEX treatment does not seem to decrease CAIX expression in the tumor. 
This can be attributed to the aforementioned resistance to enolase 
inhibition treatment by ENO1-WT cells.
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Figure 3. Decreasing hypoxia following ENO2 knockdown. (A) CAIX expression increases as O2 concentration 
lessens. ENO2 increases as the environment becomes more hypoxic. GAPDH loading control remains relatively 
constant. (B) ENO2 quantity is expressed as a ratio to the loading control Glyceraldehyde-3-Phosphate Dehydrogenase 
(GAPDH) in decreasing concentrations of O2 for ENO2-silenced and expressed conditions. There is a consistent 
decrease in ENO2 across all concentrations after knockdown by shRNA, likely indicating an increase in metabolic 
enzyme activity in response to hypoxia. Conversely, as conditions become more hypoxic, CAIX increases significantly 













Figure 3. Treating cells with POMHEX reduces hypoxia (A) CAIX activity is significantly decreased at all 
concentrations of treatment. CPT1A increases in expression following POMHEX treatment.The loading control vinculin is 
relatively constant. (B) CAIX quantity is expressed as a ratio of the loading control Vinculin, an actin-binding protein in the 
cell that does not change expression levels in hypoxia.  In 21% and 5% O2, treatment significant decreases CAIX 
expression. This supports our hypothesis that hypoxia can be decreased with enolase inhibition.
Drug Treatment: 
• We decided to use HEX, a substrate-competitive 
enolase inhibitor, and its prodrug POMHEX
• POMHEX is a cell-permeable pivaloyloxymethyl 
(POM) prodrug that can act with greater potency in 
vivo
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